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Abstract
Dicopper(II) tetrakis(3,5-diisopropylsalicylate), [Cu(II)a(3,5-DIPS)a], is effective in increasing
survival of lethally irradiated mice when it is administered after irradiation. The possibility that this
radiorecovery activity might also facilitate recovery from radiation-induced impaired increase in body mass
and locomotion was examined. Cu(II)z(3,5-DIPS)4 was used to treat LD;0/30 gamma irradiated female
C57BL/6 mice after irradiation. A dose of 0, 5, 10, or 20 mol Cu(II)z(3,5-DIPS)4/kilogram of body mass
was administered subcutaneously 3 hrs aider LDs0/30 irradiation and change in body mass and locomotor
activity measured daily throughout the 30 day post-irradiation period. Treatment with 5, 10, or 20 tmol
Cu(II)z(3,5-DIPS)4/kg of body mass increased survival, which was statistically significant for the 10 lamol/kg
ofbody mass-treated group compared to the vehicle-treated group (P<0.05), significantly (P<0.05) increased
recovery of locomotion from days 13 to 15 post-irradiation onward for all treated groups compared to
vehicle-treated mice, and increased recovery of body mass gain from day 14 onward for the 20 lamol/kg of
body mass-treated group (P<0.001) and day 21, although not statistically significant, for the 10 mol/kg of
body mass-treated group. There were no statistically significant differences between the increase in survival,
recovered increase in body mass, and recovered increase in locomotion for mice treated with 10 lamol or 20
lamol Cu(II)z(3,5-DIPS)4/kg on day 30 post-irradiation. It is concluded that Cu(II)z(3,5-DIPS)4 in addition to
increasing survival of irradiated mice increases the rate of recovery ofradiation-induced decrease in body mass
and locomotion.
Introduction
Ionizing radiation causes physical and behavioral decrements in humans. Acute radiation injury
produces physical symptoms of fatigue, weakness, nausea, emesis, and diarrhea which considerably alter
physical behavior. Limited data regarding cognitive behavioral decrements associated with people exposed to
radiation document decreased brain blood flow, a marked increase in anticipatory stress, and reduced
performance level causing such problems as impaired completion of imbedded-figures tasks and decreased
persistence in solvable behavior tasks when compared with a non-irradiated control groups 1,2]. These tests
are used to measure speed and accuracy in decision making of subjects who must reappraise their situation
continually and make constant decisions in their attempt to find the correct pathway through a maze as
rapidly as possible and with the fewest mistakes. The ability to undertake rescue efforts and understand the
behavior decrements of irradiated individuals, which include themselves, following a nuclear accident or
radiation exposure of space crews is a matter which will require the attention of those responsible for
protection of both the civilian population and astronauts. Understanding that radiation-induced alterations in
behavior are likely to interfere with the effective functioning of rescue teams and space mission crews deserves
further study [3].
Radiation injury also effects the health and behavior of animals. Mice express symptoms similar to
humans including reduced body mass and locomotion [3-7]. Mice exhibit decreased locomotor activity in an
open field maze, and perform poorly in shock avoidance and roto-rod tests as a result of radiation exposure
[5]. Radiation-induced Performance Decrement (PD) occurring in mice begins with Early Transient
Incapacitation (ETI) period and continues for at least 30 days post irradiation [6,7]. Exposure to ionizing
radiation has been shown to decrease locomotor activity as much as 40% for an entire 150 day post
irradiation period [7].
Several compounds have been tested throughout the entire post-irradiation period for mitigation of
PD. Caffeine, a central nervous system stimulant, was shown to reduce PD in mice following irradiation but
provided no protection against lethality [8].
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Three radioprotectants, WR- 1065, 2[(3-aminopropyl)amino]propanethiol, WR-2721, 2[(3-amino-
propyl)amino]ethanethiol dihydrogen phosphate ester and WR-3689, 2[(3-methylaminopropyl)amino]-
ethanethiol dihydrogen phosphate are effective in increasing survival at doses close to their LD;0 doses.
Their acute toxicities in humans caused them to be abandoned as radioprotectants. The effective
radioprotectant dose of these drugs is such that their concomitant acute and behavioral toxicities causes them
to be unacceptable for situations where rapid and skilled performance is required [7,9]. An even greater
concern is that WR-2721 acting synergistically with the stress of roto-rod performance causes an increase in
lethality [6].
During space travel, astronauts will be placed in physically and intellectually demanding situations.
Thus, although WR-2721 is an effective protector against lethality, it is not an effective protector against PD
[6]. The search then continues for a compound that has two very important activities, protecting against
radiation lethality and decreasing radiation-induced behavioral decrements or at the very least not
exacerbating them.
It has been shown that post-irradiation treatment with Cu(II)z(3,5-DIPS)4 increases the rate of recovery
of immunocompetency and histopathology and it increases survival of irradiated mice at doses much lower
than its LDs0 dose(10). The LDs0 dose is 13 times greater than the maximally effective dose of this
complex, 20 t.tmol/kg of body mass, when given to female mice before irradiation(10). Treatment with 2.5,
5, or 10 tmol/kg of body mass Cu(II)z(3,5-DIPS)4 which are 1/26 to 1/105 the LD0 dose in female mice,
produced survival of 88%, 92%, or 92% respectively.
Objectives of this study were to determine whether or not Cu(II)z(3,5-DIPS)4 treatment atter
irradiation facilitates recovery from radiation-induced behavioral decrements and recovery of lost body mass
in a dose-response manner. Results of this study demonstrate that treatment with Cu(II)z(3,5-DIPS)4 does
facilitate recovery of radiation-induced loss of body mass and behavioral (locomotion) decrements in
conjunction with an increase in survival in a dose related fashion.
Methods
Purified 3,5-diisopropylsalicylic acid was purchased from Aldrich Chemical Company. Copper(II)
chloride dihydrate purchased from Spectrum Chemical Company was used without further purification.
Cu(II)z(3,5-DIPS)4 [12] was synthesized according to published methods [13]. Polyvinyl alcohol (P-1763)
was purchased from Sigma. Propylene glycol (Sigma) was microbiologically purified by Millipore filtration
through a 0.2 lam filter. A 1.4% mass/volume polyvinyl alcohol (Sigma) solution was prepared by
dissolving 3.5 mg of polyvinyl alcohol in saline at 90C with stirring, cooling to room temperature, and
diluting to 250 ml.
Suspensions of Cu(II)z(3,5-DIPS)4 were prepared in a Bellco HEPA laminar flow hood (Bellco
Technologies, Vineland, New Jersey) by first wetting the complex with 4 grams of propylene glycol, 4%
mass/volume of the final suspension, in a glass Potter-Elvejhem homogenizer with a Teflon pestle, and
diluting with 1.4% polyvinyl alcohol in saline. The resulting paste was gradually diluted with polyvinyl
alcohol in saline with homogenization. This suspension was then slowly diluted to the final volume in a
graduated cylinder with the rinse from the homogenizer and mixed by vortex stirring. A volume of 0.5 ml of
this suspension contained the 20 lamol/kg of body mass dose of complex. Twelve and one-half milliliters of
this suspension was then diluted 1"1 with a solution of4% propylene glycol and 1.4% polyvinyl alcohol in
saline to obtain a suspension containing the 10 lamol/kg of body mass dose in 0.5 ml of suspension. This
dilution procedure was repeated to obtain a suspension containing the 10 lamol/kg ofbody mass dose in 0.5
ml of suspension.
All suspensions were vortex stirred prior to administration and stirred throughout the administration
period as a standard procedure. All doses were administered with all-glass syringes to avoid contamination
from rubber tips on pistons of disposable syringes by zinc and copper compounds used in molding and to
prevent oxidation, respectively, of these tips.
Single-Dose samples (0.5 ml) were placed in metal-free culture tubes prior to initiation of treatment
and after treatment of each group. These samples were subsequently analyzed for copper by atomic absorption
spectrophotometry using established interference-free methods [14] and diluted Cation Cal (Baxter Health
Care Corp., Miami, Florida) as an external standard to determine the actual treatment dose. These
determined doses were found to vary within +5% of the intended dose. This procedure is recommended to
provide assurance that the actual dose given is the intended dose.
All animal experiments were approved by the institution’s Animal Care and Use Committee which
has an Animal Welfare Assurance on file with the Office of Protection from Research Risks.
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One hundred C57BL/6 nine-week old 19 to 21 gram female mice acclimatized to 12-h 6:00 am to
6:00 pm light/dark cycle and constant 720 C temperature quarters were randomly assigned to one of 20
Polycarbonate (11.5"L X 7.5"W X 5:H) cages, five per cage, and given food and water ad libitum. These
mice were ear-punched under a mild anesthesia (Metafane) for identification. Prior to irradiation, individual
average locomotion was determined for all mice for two minutes to establish a normal level of activity on
consecutive days in the morning in an empty cage placed on an Automex Locomotion Counter (Columbus
Instruments, Columbus, Ohio). The Sensitivity Level was set at 100 using 2 inch strip of aluminum foil
around the top of the cage. Mice usually have a large variation in activity and having them serve as their
own control allowed the determination of change in the morning (locomotion) movement about the cage
beginning on the day following irradiation and treatment using the same cage size and activity devices.
Body mass was measured daily following the determination of locomotion throughout the experiment.
All mice received a whole body dose of 8 Gy, 1.3 8 Gy/min, from 1100 to 1215 hrs Central Standard
time. For irradiation two mice were placed in one of four well-ventilated, Plexiglas containers and placed
into a J.L. Shepherd and Associates model 143-45 Cesium-137 irradiator. Mice in each group received a
subcutaneous treatment of 0 (vehicle), 5, 10, or 20 gmol Cu(II)2(3,5-DIPS)4/kg of body mass three hours
post-irradiation. Survival at the end of a 30-day period after irradiation was determined as the measure of
radiation recovery. Statistical significance of survival data was analyzed by the Fisher Exact Two-Tailed
method. Comparisons of body mass measurements and locomotion counts were analyzed using the one-way
ANOVA. Post-hoc Comparisons were made using Dunnett’s test (P<0.05).
Results
Cu(II)2(3,5-DIPS)4 did facilitate the increase in survival of irradiated mice. As shown in Figure 1,
mice treated with 0, 5, 10, or 20 mol Cu(II)2(3,5-DIPS)a/kg of body mass 3 hours alter LD0/30 irradiation
exhibited survivals of 32%, 52%, 60%, or 52% respectively. These data represent increases in survival of
63% for the 5 and 20 lamol/kg of body mass-treated groups and an 88% increase in survival of the 10
I.tmol/kg of body mass-treated group which is significantly (P<0.05) greater than survival observed for
vehicle-treated mice. Treatment, as anticipated, did not cause acute toxicity in that irradiated mice treated
with various doses of Cu(II)2(3,5-DIPS)4 did not die before mice treated with vehicle. Mice in the vehicle-
treated group began dying before mice in the Cu(II)2(3,5-DIPS)4-treated groups.
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Figure 1. Survival of female C57BL/6 mice treated with vehicle (B), 5 mol (), 10 tmol (O), or
20 ktmol )Cu(II)z(3,5-DIPS)4/kg ofbody mass 3 hr after day zero, the day of irradiation.
Average body mass of Cu(II)2(3,5-DIPS)4-treated mice recovered more rapidly than that of the vehicle-
treated control group. Figure 2 shows the average daily body mass for vehicle-treated Cu(II)2(3,5-DIPS)4-
treated groups. The average body mass for all treatment groups followed approximately the same trend until
day 14 when the 20 lamol/kg of body mass-treated group began a sharp increase in average body mass which
became significantly (P<0.05) different from the increase in body mass observed for the vehicle-treated group
on day 30. A less dramatic and not statistically significant increase in average body mass was exhibited by
the 10 lamol/kg of body mass-treated group on day 21 and remained distinct from both the 0 gmol/kg of
body mass and 5 lamol/kg of body mass groups through day 30. The vehicle-treated and the 5 lamol/ kg of
body mass-treated groups exhibited similar and not significantly different changes in average body mass
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throughout the study. Treatment with 10 tmol/kg or 20 tmol/kg appears to have produced a dose-related
increase in body mass that was observed after days 21 or 16 respectively.
TIME AFTER IRRADIATION(DAY)
Figure 2. Average body mass change for female C57BL/6 mice treated with vehicle
(I), 5 lamol (), 10 mol (O), or 20 lamol Cu(II)2(3,5-DIPS)4/kg of
body mass 3 hr after day zero, the day of irradiation.
All groups displayed a decrease in average daily locomotion activity following irradiation (Figure 3).
Cu(II)z(3,5-DIPS)4-treated groups began to increase locomotor activity between days 13 and 15 which
continued to increase until day 30. Locomotion of the vehicle-treated group recovered only slightly by day
30. Average daily locomotor activity for all Cu(II)z(3,5-DIPS)4-treated mice rapidly recovered from day 15
onward and this recovery was significantly (P< 0.001) related to increasing dose of Cu(II)z(3,5-DIPS)4 on
day 30.
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Figure 3. Average change in locomotion of female C57BL/6 mice treated with vehicle (I), 5 mol
(), 10 mol (O), or 20 lamol Cu(II)z(3,5-DIPS)a/kg of body mass 3 hr after day zero,
the day of irradiation.
Discussion
The initial phase of Performance Decrement is correlated with a drop in blood pressure and cerebral
blood flow [15]. Nitric Oxide (NO), the Vascular Endothelium Derived Relaxing Factor(EDRF) has been
shown to be a potent vasodilator and hypotensive agent [15]. Nitric Oxide has also been shown to be found
in the largest quantities, with respect to other parts of the brain, in the cerebellum [15]. The possibility that
radiation might increase the production ofNO would account for the observed decrease in blood pressure and
cerebral blood flow [17]. A compound that would down-regulate nitric oxide synthase and thus the
production ofNO would therefore attenuate the decrease in blood pressure and cerebral blood flow.
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Chemicals that directly modulate these two physiological events were studied in order to attenuate
behavioral disruption. Direct attenuation with the blood pressure stabilizer norepinephrine was not
successful, possibly because the relationship between behavior and blood pressure changes is not always
direct [17]. A substance that will prevent the loss of blood flow to cerebral areas and restore normal blood
pressure by inhibiting mechanisms responsible for these decrements is needed rather than a substance that
simply treats the occurrence of these events.
Recent studies suggest that Cu(II)z(3,5-DIPS)4 down-regulates Nitric Oxide Synthase [18] which is
necessary for the production ofNO. Inhibition ofNO synthesis may prevent radiation-induced vasodialation
and hypotension. It has also been suggested that the regulation of vasodilation may play a role in radiation
protection (18). The present report offers support for the possiblity that recovery from radiation-induced
vasodilation plays a role in radiation recovery.
It has been shown that post-irradiation treatment with non-toxic doses of Cu(II)z(3,5-DIPS)4 increases
the rate of recovery of immunocompetency and histopathology as well as survival of irradiated mice 10,11 ].
These reports included data showing the Therapeutic Index, LDs0/EDs0, of Cu(II)z(3,5-DIPS)4 to be 13.1
when using a 20 gmol/kg body of mass dose, the largest dose used in the present studies, to achieve
radioprotection/radiorecovery. It should be noted that 10 is the ideal Therapeutic Index, which is a measure
of safety in use.
Treatment with non-toxic doses of Cu(II)z(3,5-DIPS)4 used in this study also enabled rapid recovery
of radiation-induced impaired locomotion and loss of body mass. Since radiation causes long-term
impairment, which is not corrected with existing radioprotectants, the use of Cu(II)z(3,5-DIPS)4 offers an
additional advantage as a radioprotectant and radiorecovery agent.
Conclusion
Results obtained in this study strongly support the hypothisis that Cu(II)2(3,5-D|PS)4 is effective in
facilitating the recovery of radiation-induced behavioral decrements and confirm the previous report that
treatment with Cu(II)2(3,5-DIPS)4 alter LDs0/30 irradiation is an effective radiorecovery measure. This
radiorecovery activity is consistent with rapid recovery of immunocompetency, repair of radiation-induced
histopathology, and impaired locomotion.
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